Back

Use and timing of guideline-directed medical therapy before and after hospitalization for heart failure: from the EMPACE study

18 May 2025 (16:00 - 16:45)
Organised by: Logo
Congress Presentation Part of: Vericiguat, SGLT2 inhibitors and implementation Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)

6 More presentations in this session

Presentation thumbnail
A placebo-correcetd effect of the initial eGFR decline following SGLT-2 inhibitor initiation: a systematic review and meta-analysis
Doctor S. Urban (Lubin, PL)
Abstract Slides Video
Presentation thumbnail
Scarred for life - outcomes of ischaemic and non-ischaemic cardiomyopathy after heart failure optimisation
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video
Presentation thumbnail
Estimated multinational budget impact of empagliflozin for heart failure patients with full spectrum of left ventriclular ejection fraction
Doctor E. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Vericiguat in a real-world heart failure population: a single-centre experience
Mr C. Palacios-Castello (Seville, ES)
Abstract Slides Video
Presentation thumbnail
Quantifying the burden of potentially inappropriate prescribed medicines among people hospitalised with heart failure in Australia: a comparison with ESC recommendations
Associate Professor M. Falster (Sydney, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Vericiguat, SGLT2 inhibitors and implementation

The Event

Event poster

Heart Failure 2025

18 May 2025 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Outpatient prescribing of guideline-directed medical therapy in heart failure
thumbnail
Congress Presentation
Pre- and post- discharge implementation of medical therapy in patients hospitalized due to acute heart failure: a multinational observational registry
thumbnail
Congress Presentation
Effect of improving utilization of guideline-directed medical therapy for heart failure.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources